UNSPSC 51241544: Phenylephrine/zinc sulfate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP900. This VA Drug Class (OP900) classifies this compound as belonging to the group OPHTHALMICS, OTHER.

UNSPSC 51241544 Phenylephrine/zinc sulfate, a Commodity code, covers pharmaceutical products supplied through cooperative purchasing agreements to state and local government health care and institutional facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits manufacturers to supply generic multi-source pharmaceuticals and over-the-counter products under master agreements that serve participating state agencies, counties, municipalities, and other public bodies across multiple states including Oregon. Vendors supply through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC — and must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with at least two of the three wholesalers with chargeback systems in place, and demonstrate pricing flexibility through formats including flat price, net price (NF30, NF60, NF90), or WAC-minus structures. Award evaluation weights price competitiveness at 75 percent, with fixed pricing, administrative fee compliance, EDI capability, and fee agreement each weighted at 5 to 10 percent.

MMCAP's RFP S1070000015802, posted January 20, 2026 with response deadline March 26, 2026, is the primary recent activity under this code. The contract term runs two years for new responders with optional extensions at MMCAP's discretion; incumbent responders' amendments align with existing agreement expiration through June 30, 2028. Awarded vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials. All products must be available in the marketplace by May 15, 2026, possess FDA compliance, carry expiration dates of at least one year from manufacture with a minimum six-month shelf life, and vendors must maintain comprehensive insurance including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability.